OMNI Health Media is a leading online provider of Daily Health News. OMNI’s KEYNOTE-059 Programmed Death-ligand 1 News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

September 18, 2017

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

By Anonymous User anonymous_user_10987

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, immunotherapy, KEYNOTE-059 programmed death-ligand 1, keytruda, metastatic gastric cancer, News Tips and Features, News Tips and Features Other, PD-L1, pembrolizumab, Precision Cancer Medicine, stomach cancer

View more articles like this
More news and in-depth Gastric Cancer information